Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, estudio No reclutando aún

Not Yet Recruiting

ID del estudio CA266-0004  |   NCT07221149

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Ícono de advertencia
Lo sentimos, este estudio aún no acepta participantes.
Marque esta página como favorita para volver a consultarla en una fecha posterior.  También puede hacer clic en el botón “Verificar su elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad

Resumen

  • Phase 2/Phase 3
  • Ícono de género masculino y femenino
  • 18+
  • 71
  • Ícono de BMS, estudio No reclutando aún
    Not Yet Recruiting

Descripción general

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must be previously untreated with systemic treatment for advanced/metastatic disease, histologically or cytologically confirmed advanced or metastatic gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJC) or distal esophageal adenocarcinoma (EAC). GEJ involvement can be confirmed via biopsy, endoscopy, or imaging.
    1. Participants must have a documented programmed cell death-(ligand)1 (PD-L1) ≥ 1.
      1. Participants must have documented human epidermal growth factor receptor 2 (HER2)-negative cancer, as determined according to local guidelines.
        1. Participants must have measurable disease as defined by RECIST v1.1.

          Criterios de exclusión

          Criterios de exclusión Icon
          • Participants must not have untreated known central nervous system (CNS) metastases.
            1. Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
              1. Participants must not have evidence of major coagulation disorders (eg, hemophilia).
                1. Participants must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 3 months prior to randomization, unless the participant has been fully treated (eg, inferior vena cava filter placed) and/or adequately anticoagulated on a prophylactic dose.
                  1. Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months of randomization.
                    1. Participants must not have had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study intervention.
                      Información Adicional *
                      • Other protocol-defined Inclusion/Exclusion criteria apply.

                        Opciones de tratamiento

                        Brazos del estudio

                        INTERVENCIÓN ASIGNADA

                        Brazos del estudio

                        Experimental: Arm A1

                        INTERVENCIÓN ASIGNADA
                        • Drug: Pumitamig, Folfox

                        Brazos del estudio

                        Experimental: Arm A2

                        INTERVENCIÓN ASIGNADA
                        • Drug: Pumitamig, Folfox

                        Brazos del estudio

                        Experimental: Arm B

                        INTERVENCIÓN ASIGNADA
                        • Drug: Folfox, Nivolumab

                        Brazos del estudio

                        Experimental: Arm C

                        INTERVENCIÓN ASIGNADA
                        • Drug: Pumitamig, Folfox, Capox

                        Brazos del estudio

                        Experimental: Arm D

                        INTERVENCIÓN ASIGNADA
                        • Drug: Folfox, Capox, Nivolumab
                        Vuelva a consultar más tarde para encontrar un sitio de reclutamiento o encuentre otro estudio haciendo clic en “Verificar su elegibilidad”
                        Verifique su elegibilidad
                        Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                        Compatibilizar con un estudio
                        Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                        Seleccione una ubicación del centro del estudio
                        Seleccione una ubicación del centro del estudio que sea conveniente para usted
                        Registrarse
                        Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                        Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias